By Mill Chart
Last update: May 7, 2024
Our stock screening tool has pinpointed NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) as a growth stock that isn't overvalued. NYSE:NVO is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.
To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NYSE:NVO has achieved a 7 out of 10:
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NYSE:NVO, the assigned 5 reflects its valuation:
ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NYSE:NVO, the assigned 7 for health provides valuable insights:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:NVO scores a 9 out of 10:
Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.
For an up to date full fundamental analysis you can check the fundamental report of NVO
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (5/17/2024, 7:17:01 PM)
After market: 131.65 -0.24 (-0.18%)131.89
-1.15 (-0.86%)
The market has flashed a green signal to investors.
Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two.
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason.
Could Amgen be the next stock to soar due to a GLP-1 drug?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
This company is serious about maintaining its leadership.
Both of these businesses are finding traction in a pair of major markets.
This mid-cap biopharma may one day be a titan of the industry.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably.